Intravenous N‐acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo‐controlled clinical trial

Robert H. Squires, Anil Dhawan, Estella Alonso, Michael R. Narkewicz, Benjamin L. Shneider, Norberto Rodriguez‐Baez, Dominic Dell Olio, Saul Karpen, John Bucuvalas, Steven Lobritto, Elizabeth Rand, Philip Rosenthal, Simon Horslen, Vicky Ng, Girish Subbarao, Nanda Kerkar, David Rudnick, M. James Lopez, Kathleen Schwarz, Rene Romero, Scott Elisofon, Edward Doo, Patricia R. Robuck, Sharon Lawlor, Steven H.

Progressive graft fibrosis and donor‐specific human leukocyte antigen antibodies in pediatric late liver allografts

Aya Miyagawa‐Hayashino, Atushi Yoshizawa, Yoichiro Uchida, Hiroto Egawa, Kimiko Yurugi, Satohiro Masuda, Sachiko Minamiguchi, Taira Maekawa, Shinji Uemoto, Hironori Haga – 10 August 2012 – The role of donor‐specific anti‐human leukocyte antigen antibodies (DSAs) that develop late after living donor liver transplantation is unknown. Seventy‐nine pediatric recipients who had good graft function and underwent protocol liver biopsy more than 5 years after transplantation (median = 11 years, range = 5‐20 years) were reviewed.

Clinical yield of diagnostic endoscopic retrograde cholangiopancreatography in orthotopic liver transplant recipients With suspected biliary complications

B. Joseph Elmunzer, Anthony T. DeBenedet, Michael L. Volk, Christopher J. Sonnenday, Akbar K. Waljee, Robert J. Fontana, Aarti B. Oza, Amit Singal, Michael J. Englesbe, James M. Scheiman – 10 August 2012 – Diagnostic endoscopic retrograde cholangiopancreatography (D‐ERCP) is commonly performed for the evaluation of biliary complications after orthotopic liver transplantation (OLT). This practice is contrary to the national trend of reserving endoscopic retrograde cholangiopancreatography (ERCP) for therapeutic purposes.

Yes‐associated protein regulates the hepatic response after bile duct ligation

Haibo Bai, Nailing Zhang, Yang Xu, Qian Chen, Mehtab Khan, James J. Potter, Suresh K. Nayar, Toby Cornish, Gianfranco Alpini, Steven Bronk, Duojia Pan, Robert A. Anders – 8 August 2012 – Human chronic cholestatic liver diseases are characterized by cholangiocyte proliferation, hepatocyte injury, and fibrosis. Yes‐associated protein (YAP), the effector of the Hippo tumor‐suppressor pathway, has been shown to play a critical role in promoting cholangiocyte and hepatocyte proliferation and survival during embryonic liver development and hepatocellular carcinogenesis.

Burden of de novo malignancy in the liver transplant recipient

Natasha Chandok, Kymberly D. Watt – 6 August 2012 – Recipients of liver transplantation (LT) have a higher overall risk (2‐3 times on average) of developing de novo malignancies than the general population, with standardized incidence ratios ranging from 1.0 for breast and prostate cancers to 3‐4 for colon cancer and up to 12 for esophageal and oropharyngeal cancers.

Risk of cytomegalovirus disease in high‐risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta‐analysis

Andre C. Kalil, Cezarina Mindru, Jean F. Botha, Wendy J. Grant, David F. Mercer, Marco A. Olivera, Megan A. McCartan, Timothy M. McCashland, Alan N. Langnas, Diana F. Florescu – 6 August 2012 – Valganciclovir (VGC) was approved by the Food and Drug Administration in 2004 as cytomegalovirus (CMV) prophylaxis except for liver transplant recipients because of their high incidence of CMV disease with this drug. However, surveys have shown its common off‐label use for CMV prophylaxis in liver transplant recipients.

Subscribe to